Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Net Margin: 2010-2025

Historic Net Margin for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to -92.91%.

  • Lineage Cell Therapeutics' Net Margin fell 1350.00% to -92.91% in Q3 2025 from the same period last year, while for Sep 2025 it was -296.07%, marking a year-over-year decrease of 6616.00%. This contributed to the annual value of -195.62% for FY2024, which is 4450.00% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Net Margin stood at -92.91% for Q3 2025, which was up 86.71% from -698.95% recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Net Margin peaked at -56.02% during Q4 2021, and registered a low of -969.73% during Q2 2021.
  • Over the past 3 years, Lineage Cell Therapeutics' median Net Margin value was -225.77% (recorded in 2023), while the average stood at -308.74%.
  • In the last 5 years, Lineage Cell Therapeutics' Net Margin skyrocketed by 126,936bps in 2021 and then plummeted by 37,048bps in 2023.
  • Lineage Cell Therapeutics' Net Margin (Quarterly) stood at -56.02% in 2021, then plummeted by 27,620bps to -332.22% in 2022, then skyrocketed by 10,645bps to -225.77% in 2023, then spiked by 11,245bps to -113.32% in 2024, then plummeted by 1,350bps to -92.91% in 2025.
  • Its last three reported values are -92.91% in Q3 2025, -698.95% for Q2 2025, and -401.26% during Q1 2025.